Jump to content

Regulatory B cell

From Wikipedia, the free encyclopedia
(Redirected from Regulatory B cells)

Regulatory B cells (Bregs or Breg cells) represent a small population of B cells that participates in immunomodulation and in the suppression of immune responses. The population of Bregs can be further separated into different human or murine subsets such as B10 cells, marginal zone B cells, Br1 cells, GrB+B cells, CD9+ B cells, and even some plasmablasts or plasma cells. Bregs regulate the immune system by different mechanisms. One of the main mechanisms is the production of anti-inflammatory cytokines such as interleukin 10 (IL-10), IL-35, or transforming growth factor beta (TGF-β). Another known mechanism is the production of cytotoxic Granzyme B. Bregs also express various inhibitory surface markers such as programmed death-ligand 1 (PD-L1), CD39, CD73, and aryl hydrocarbon receptor. The regulatory effects of Bregs were described in various models of inflammation, autoimmune diseases, transplantation reactions, and in anti-tumor immunity.[1][2][3]

History

[edit]

In the 1970s it was noticed that Bregs could suppress immune reaction independently of antibody production.[4] In 1996 Janeway's group observed an immunomodulation of experimental autoimmune encephalomyelitis (EAE) by B cells.[5] Similar results were shown in a model of chronic colitis one year later.[6] Then a role of Bregs was found in many mouse models of autoimmune diseases as rheumatoid arthritis[7] or systemic lupus erythematosus (SLE).[8]

Development and populations

[edit]

Bregs can develop from different subsets of B cells such as immature and mature B cells or plasmablasts. Whether Breg cells uniquely derive from a specific progenitor or originate within conventional B cell subsets is still an open question.[1][9] Unfortunately, Breg cells are more difficult to define than regulatory T cells (Tregs) since they lack a lineage marker analogous to the Treg cell marker - FOXP3.[10] Bregs share many markers with various B cell subsets due to their origin. Human and murine Bregs can be further separated into many subsets due to their different mechanism of action and distinct expression of key surface markers (table below). It is estimated that IL-10 producing B cell subpopulations can constitute up to 10% of circulating human B cells.[11] There is still no clear consensus on the classification and definition of Breg cells.[1] Mouse Bregs were mainly CD5 and CD1d positive in the model of EAE or after the exposition of Leishmania major.[12][13] By contrast, mouse Bregs in model of collagen-induced arthritis (CIA) were mainly CD21 and CD23 positive.[14] Bregs were found in humans, too. Markers of peripheral blood Bregs were molecules CD24 and CD38.[15] However, peripheral blood Bregs were mostly CD24 and CD27 positive after cultivation with anti-CD40 antibody and CpG bacterial DNA.[16] They were also positive for CD25, CD71 and PD-L1 after stimulation by CpG bacterial DNA and through TLR9.[17]

Breg subsets identified in human or mice
Subset Species Phenotype Function
B10 cells human, mouse CD24hiCD27+ (human), CD5+CD1dhi (mouse) production of IL-10, suppression of effector CD4+ T cells, monocytes, and DCs[1][2]
Plasmablasts human, mouse CD19+CD24hiCD27int (human), CD138+CD44hi (mouse) production of IL10 and TGF-β, suppression of DCs and effector CD4+ T cells [1][2][3]
Plasma cells mouse CD138+MHC-11loB220+ production of IL-10 and IL-35, suppression of NK cells, neutrophils, and effector CD4+ T cells [1][2][3]
Marginal zone B cells human, mouse CD19+CD21hiCD23− production of IL-10, induction of Treg cells, suppression of effector CD4+ and CD8+ T cells[1][2][3][11]
Br1 cells human CD19+CD25hiCD71hi CD73− production of IL-10, suppress inflammatory responses, induction of Treg cells and promotion of IgG4 production[1]
GrB+B cells human CD19+CD38+CD1d+IgM+CD147+ production of granzyme B, degradation of T cell receptor, inhibition of CD4+ T cell proliferation and Th1 and Th17 responses [1][3]
CD9+ B cells human, mouse CD19+CD9+ production of IL-10, suppression of Th2 and Th17 inflammation[1]
CD5+CD1d+ cells human CD19+CD5+CD1dhi production of IL-10, suppression of Th17 response[1]
B1a cells mouse CD19+CD5+ production of IL-10, suppression of TLR-mediated inflammation[1]
Killer B cells mouse CD19+CD5+FasL+ induction of T cell death[1]
Tim-1+ B cells mouse Tim−1+CD19+ production of IL-10, enhance Th2 and Treg responses, regulation of Th1 and Th17 cells during inflammation[1][18]
Transitional 2-marginal zone precursor cells mouse CD19+CD21hiCD23hi production of IL-10, suppression of effector CD4+, CD8+ T cells and induction of Treg cells[1][2][19]

Mechanisms of action

[edit]
Structure of interleukin 10 (IL-10). Key player in Breg biology.

There are several mechanisms of Breg action. Nevertheless, the most examined mechanism is the production of IL-10. IL-10 has strong anti-inflammatory effects.[20][21] It inhibits (or suppresses) inflammatory reactions mediated by T cells, especially Th1 and Th17 type immune reactions. This was shown for example in the models of EAE,[22] CIA[23] or contact hypersensitivity.[24] Likewise, regulatory B cell subsets have also been demonstrated to inhibit Th1 responses through IL-10 production during chronic infectious diseases such as visceral leishmaniasis.[25] By production of IL-10, Bregs are also capable of conversion of naïve CD4+ T cells into Tregs and IL-10-secreting type 1 regulatory CD4+ T cells. This has been observed in various experimental models as well as chronically virus-infected patients.[3] Another mechanism of Breg suppression is the production of transforming growth factor (TGF-β), an anti-inflammatory cytokine.[20] The role of Bregs producing TGF-β was found in the mouse models of SLE [8] and diabetes.[26] The last anti-inflammatory cytokine produced only by some Bregs is IL-35, which plays a role in Treg conversion. Breg cells are capable of releasing IL-35 containing exosomes. It is not yet clear whether IL-10 and IL-35-producing Bregs correspond to separate populations or display some degree of overlap.[3] Besides the production of immunomodulatory cytokines, Bregs also release cytotoxic granzyme B involved in the degradation of the T cell receptor and T cell apoptosis.[11] Another mechanism of Breg suppression involves surface molecules such as FasL, which induces T cell death,[27] or PD-1 and PD-L1. PD-1+ Bregs have been shown to suppress CD4+ and CD8+ T cell activity and induce Tr1 cells, while PD-L1 Bregs were reported to inhibit NK and CD8+ T cell cytotoxicity.[3] Some Bregs also express additional suppressive molecules such as CD39, CD73, and aryl hydrocarbon receptor.[1]

Activation

[edit]

Resting B lymphocytes do not produce cytokines. After the response to antigen or different stimuli such as lipopolysaccharide (LPS) pro- and anti-inflammatory cytokines TNFα, IL-1β, IL-10 and IL-6 are produced. This indicates that the Breg must be stimulated to produce suppressive cytokines. There are two types of signals to activate Breg, namely signals generated by external pathogens (PAMPs) and endogenous signals produced by the action of body cells. PAMPs are recognized by the toll-like receptors (TRLs). TLRs trigger a signal cascade at the end of which is the production of effector cytokines. Bregs are mainly generated after the recognition of TLR4 or TLR9 ligands - LPS and CpG. The main endogenous signal is the stimulation of the surface molecule CD40.[1][2] Some anti-inflammatory factors, such as IL-35 and retinoic acid have also been proposed to induce Breg phenotype. Additionally, cytokine IL-21 together with CD40 ligand and/or TLR9 signals has been shown to induce B10 generation and the emergence of IL-10 producing plasmablasts during inflammatory processes.[3]

Autoimmune diseases

[edit]

Bregs are studied in several human autoimmune diseases such as multiple sclerosis (MS), rheumatoid arthritis, SLE, type 1 diabetes, or Sjögren's syndrome. Generally, Breg cells seem to be important in preventing autoimmune diseases and are often reported reduced or with impaired inhibitory abilities in autoimmunity.[1][28]

Multiple sclerosis

[edit]

The main reported mechanism of Breg reduction of MS is the production of IL-10, IL-35, and TGF- β. Bregs have been extensively studied in the mouse model of multiple sclerosis - EAE, where the depletion of Bregs worsened the disease and increased the number of autoreactive T cells, but it is not clear whether the frequencies of Breg cells are altered in MS patients. Although one study reported normal Breg frequencies in MS patients, a few others have observed a decreased amount of Breg cells in patients. It has been reported that an approved medication for MS treatment Glatiramer acetate increases Breg frequencies and enhances their function. Similarly, Alemtuzumab, which is an antibody that binds CD52 of T and B cells and causes apoptosis or cell lysis, increases the frequency of Bregs in patients with relapsing MS.[1]

Systemic Lupus Erythematosus

[edit]

It has been observed that patients with SLE have deficiencies in the function of Bregs. Bregs isolated from patients had been reported to lose their regulatory capacity and be unable to inhibit the expression of pro-inflammatory cytokines IFN-γ and TNF-α by CD4+ T cells compared to Bregs from healthy donors. Several studies have also noted a decrease in the percentage of IL-35+and IL-10+ Bregs cells in SLE patients.[1][29]

Type 1 Diabetes

[edit]

In mouse models, IL-10-producing Bregs have been shown to control autoimmune diabetes. In type 1 diabetes (T1D), the evidence suggests that IL-10–producing Bregs are numerically and functionally defective in patients compared to healthy donors. Bregs in T1D have decreased production of IL-10 and are unable to suppress Th1 and Th17 immune responses. Moreover, these defective Bregs are unable to convert naive CD4+ T cells in Tregs.[19][28]

Tumors

[edit]

Tumor-infiltrating B lymphocytes consist of various phenotypes, including both effector and regulatory B cells. IL-10 or Granzyme B-producing Bregs have been detected in various human cancers. Additionally, most studies have reported a positive correlation between Breg cells and Treg cells, which indicated an interaction between these subsets.[10] It has been observed that higher frequencies of IL-10-producing B cells were observed in late-stage disease samples than in early-stage samples of esophageal cancer.[30] Leukemia B cells spontaneously produce large amounts of IL-10.[31] Moreover, increased levels of Bregs were detected in the peripheral blood and bone marrow of patients with acute myeloid leukemia. IL-10-producing Bregs are also present in gastric cancer, breast cancer, head and neck squamous carcinoma, and esophageal squamous carcinoma. The evidence suggests an immunosuppressive Breg role in cancer and it is possible that cancerous proliferation uses Bregs for its escape from the immune response.[30]

Transplantation

[edit]

It has been reported that patients undergoing kidney transplantation who were subjected to B-cell depletion therapy showed a higher incidence of graft rejection. The evidence shows that immunosuppressive properties of Bregs might play an essential role in allotransplants. Murine models of allotransplantation showed that Bregs increased the duration of allograft survival and controlled Th17, Tfh, and follicular regulatory T-cell differentiation.[1] In other types of transplants, B cells can participate both in tolerance and in transplant rejection, depending on the origin of the Breg subpopulation.[32]

References

[edit]
  1. ^ a b c d e f g h i j k l m n o p q r s t u Jansen, Kirstin; Cevhertas, Lacin; Ma, Siyuan; Satitsuksanoa, Pattraporn; Akdis, Mübeccel; van de Veen, Willem (September 2021). O'Hehir, Robyn (ed.). "Regulatory B cells, A to Z". Allergy. 76 (9): 2699–2715. doi:10.1111/all.14763. ISSN 0105-4538. PMID 33544905. S2CID 232244687.
  2. ^ a b c d e f g Rosser EC, Mauri C (April 2015). "Regulatory B cells: origin, phenotype, and function". Immunity. 42 (4): 607–12. doi:10.1016/j.immuni.2015.04.005. PMID 25902480.
  3. ^ a b c d e f g h i Catalán, Diego; Mansilla, Miguel Andrés; Ferrier, Ashley; Soto, Lilian; Oleinika, Kristine; Aguillón, Juan Carlos; Aravena, Octavio (2021). "Immunosuppressive Mechanisms of Regulatory B Cells". Frontiers in Immunology. 12: 611795. doi:10.3389/fimmu.2021.611795. ISSN 1664-3224. PMC 8118522. PMID 33995344.
  4. ^ Katz SI, Parker D, Turk JL (October 1974). "B-cell suppression of delayed hypersensitivity reactions". Nature. 251 (5475): 550–1. Bibcode:1974Natur.251..550K. doi:10.1038/251550a0. PMID 4547522. S2CID 4145793.
  5. ^ Wolf SD, Dittel BN, Hardardottir F, Janeway CA (December 1996). "Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice". The Journal of Experimental Medicine. 184 (6): 2271–8. doi:10.1084/jem.184.6.2271. PMC 2196394. PMID 8976182.
  6. ^ Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, Bhan AK (November 1997). "Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice". The Journal of Experimental Medicine. 186 (10): 1749–56. doi:10.1084/jem.186.10.1749. PMC 2199135. PMID 9362534.
  7. ^ Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, Degott C, Kikutani H, Rajewsky K, Pasquali JL, Benoist C, Mathis D (April 1999). "From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins". Immunity. 10 (4): 451–61. doi:10.1016/s1074-7613(00)80045-x. PMID 10229188.
  8. ^ a b Douglas RS, Woo EY, Capocasale RJ, Tarshis AD, Nowell PC, Moore JS (August 1997). "Altered response to and production of TGF-beta by B cells from autoimmune NZB mice". Cellular Immunology. 179 (2): 126–37. doi:10.1006/cimm.1997.1149. PMID 9268496.
  9. ^ Vitale G, Mion F, Pucillo C (Nov–Dec 2010). "Regulatory B cells: evidence, developmental origin and population diversity". Molecular Immunology. 48 (1–3): 1–8. doi:10.1016/j.molimm.2010.09.010. PMID 20950861.
  10. ^ a b Laumont, Céline M.; Banville, Allyson C.; Gilardi, Mara; Hollern, Daniel P.; Nelson, Brad H. (July 2022). "Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities". Nature Reviews Cancer. 22 (7): 414–430. doi:10.1038/s41568-022-00466-1. ISSN 1474-175X. PMC 9678336. PMID 35393541.
  11. ^ a b c Menon, Madhvi; Hussell, Tracy; Ali Shuwa, Halima (January 2021). "Regulatory B cells in respiratory health and diseases". Immunological Reviews. 299 (1): 61–73. doi:10.1111/imr.12941. ISSN 0105-2896. PMC 7986090. PMID 33410165.
  12. ^ Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF (October 2008). "Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression". The Journal of Clinical Investigation. 118 (10): 3420–30. doi:10.1172/JCI36030. PMC 2542851. PMID 18802481.
  13. ^ Ronet C, Hauyon-La Torre Y, Revaz-Breton M, Mastelic B, Tacchini-Cottier F, Louis J, Launois P (January 2010). "Regulatory B cells shape the development of Th2 immune responses in BALB/c mice infected with Leishmania major through IL-10 production". Journal of Immunology. 184 (2): 886–94. doi:10.4049/jimmunol.0901114. PMID 19966209.
  14. ^ Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR, Mauri C (June 2007). "Novel suppressive function of transitional 2 B cells in experimental arthritis". Journal of Immunology. 178 (12): 7868–78. doi:10.4049/jimmunol.178.12.7868. PMID 17548625.
  15. ^ Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C (January 2010). "CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients". Immunity. 32 (1): 129–40. doi:10.1016/j.immuni.2009.11.009. PMID 20079667.
  16. ^ Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD, Hall RP, St Clair EW, Tedder TF (January 2011). "Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells". Blood. 117 (2): 530–41. doi:10.1182/blood-2010-07-294249. PMC 3031478. PMID 20962324.
  17. ^ van de Veen W, Stanic B, Yaman G, Wawrzyniak M, Söllner S, Akdis DG, Rückert B, Akdis CA, Akdis M (April 2013). "IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses". The Journal of Allergy and Clinical Immunology. 131 (4): 1204–12. doi:10.1016/j.jaci.2013.01.014. PMID 23453135.
  18. ^ Cherukuri, Aravind; Mohib, Kanishka; Rothstein, David M. (January 2021). "Regulatory B cells: TIM-1, transplant tolerance, and rejection". Immunological Reviews. 299 (1): 31–44. doi:10.1111/imr.12933. ISSN 0105-2896. PMC 7968891. PMID 33484008.
  19. ^ a b Ben Nasr, Moufida; Usuelli, Vera; Seelam, Andy Joe; D’Addio, Francesca; Abdi, Reza; Markmann, James F.; Fiorina, Paolo (15 March 2021). "Regulatory B Cells in Autoimmune Diabetes". Journal of Immunology. 206 (6): 1117–1125. doi:10.4049/jimmunol.2001127. ISSN 1550-6606. PMID 33685919. Archived from the original on Feb 2, 2023. Retrieved 22 August 2023.
  20. ^ a b Berthelot JM, Jamin C, Amrouche K, Le Goff B, Maugars Y, Youinou P (January 2013). "Regulatory B cells play a key role in immune system balance". Joint, Bone, Spine. 80 (1): 18–22. doi:10.1016/j.jbspin.2012.04.010. PMID 22858147.
  21. ^ Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F (October 1999). "An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation". The Journal of Experimental Medicine. 190 (7): 995–1004. doi:10.1084/jem.190.7.995. PMC 2195650. PMID 10510089.
  22. ^ Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM (October 2002). "B cells regulate autoimmunity by provision of IL-10". Nature Immunology. 3 (10): 944–50. doi:10.1038/ni833. PMID 12244307. S2CID 8359750.
  23. ^ Mauri C, Gray D, Mushtaq N, Londei M (February 2003). "Prevention of arthritis by interleukin 10-producing B cells". The Journal of Experimental Medicine. 197 (4): 489–501. doi:10.1084/jem.20021293. PMC 2193864. PMID 12591906.
  24. ^ Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF (May 2008). "A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses". Immunity. 28 (5): 639–50. doi:10.1016/j.immuni.2008.03.017. PMID 18482568.
  25. ^ Schaut RG, Lamb IM, Toepp AJ, Scott B, Mendes-Aguiar CO, Coutinho JF, Jeronimo SM, Wilson ME, Harty JT, Waldschmidt TJ, Petersen CA (May 2016). "Regulatory IgDhi B Cells Suppress T Cell Function via IL-10 and PD-L1 during Progressive Visceral Leishmaniasis". Journal of Immunology. 196 (10): 4100–9. doi:10.4049/jimmunol.1502678. PMC 4868652. PMID 27076677.
  26. ^ Tian J, Zekzer D, Hanssen L, Lu Y, Olcott A, Kaufman DL (July 2001). "Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice". Journal of Immunology. 167 (2): 1081–9. doi:10.4049/jimmunol.167.2.1081. PMID 11441119.
  27. ^ Lundy SK, Boros DL (February 2002). "Fas ligand-expressing B-1a lymphocytes mediate CD4(+)-T-cell apoptosis during schistosomal infection: induction by interleukin 4 (IL-4) and IL-10". Infection and Immunity. 70 (2): 812–9. doi:10.1128/iai.70.2.812-819.2002. PMC 127725. PMID 11796615.
  28. ^ a b Boldison, Joanne; Wong, F. Susan (2021). "Regulatory B Cells: Role in Type 1 Diabetes". Frontiers in Immunology. 12: 746187. doi:10.3389/fimmu.2021.746187. ISSN 1664-3224. PMC 8488343. PMID 34616408.
  29. ^ Zhu, Qiugang; Rui, Ke; Wang, Shengjun; Tian, Jie (2021). "Advances of Regulatory B Cells in Autoimmune Diseases". Frontiers in Immunology. 12: 592914. doi:10.3389/fimmu.2021.592914. ISSN 1664-3224. PMC 8082147. PMID 33936028.
  30. ^ a b Michaud, Daniel; Steward, Colleen R.; Mirlekar, Bhalchandra; Pylayeva-Gupta, Yuliya (January 2021). "Regulatory B cells in cancer". Immunological Reviews. 299 (1): 74–92. doi:10.1111/imr.12939. ISSN 0105-2896. PMC 7965344. PMID 33368346.
  31. ^ Wang X, Yuling H, Yanping J, Xinti T, Yaofang Y, Feng Y, Ruijin X, Li W, Lang C, Jingyi L, Zhiqing T, Jingping O, Bing X, Li Q, Chang AE, Sun Z, Youxin J, Jinquan T (September 2007). "CCL19 and CXCL13 synergistically regulate interaction between B cell acute lymphocytic leukemia CD23+CD5+ B Cells and CD8+ T cells". Journal of Immunology. 179 (5): 2880–8. doi:10.4049/jimmunol.179.5.2880. PMID 17709502.
  32. ^ Silva HM, Takenaka MC, Moraes-Vieira PM, Monteiro SM, Hernandez MO, Chaara W, Six A, Agena F, Sesterheim P, Barbé-Tuana FM, Saitovitch D, Lemos F, Kalil J, Coelho V (July 2012). "Preserving the B-cell compartment favors operational tolerance in human renal transplantation" (PDF). Molecular Medicine. 18 (5): 733–43. doi:10.2119/molmed.2011.00281. PMC 3409285. PMID 22252714.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Regulatory_B_cell&oldid=1241650893"